Committed to solid profitable growth

Investor Introduction

September 2026

Forward looking and intended use statements

Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Regulation G: In this presentation, QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. Adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

The **value of biology** has never been stronger



Crucial to advancing science

Improving healthcare for all

Direct impact on your lives

QIAGEN solutions are used worldwide by researchers - from young scientists to Nobel laureates - and clinical labs

QIAGEN at a glance

Highly recurring revenues

~90% Consumables and related revenues

~10% Instruments

~5,700
employees known as QIAGENers

>500,000
customers worldwide

A global company with scale

$2.09 billion sales(1)

QGEN LISTED NYSE

DAX

TecDAX

~52% Americas

~34% EMEA

~14% Asia-Pacific / Japan

Balanced customer markets

Life Sciences ~50%

R&D continuum

Molecular Diagnostics ~50%

(1) Based on 2025

QIAGEN more focused and stronger than ever



Growth and value



Balanced global presence

2025 net sales (%)

Differentiated portfolio

2025 net sales (%)



CAGR – Compound annual growth rate | Total addressable market based on QIAGEN estimates

Leading from the first step in lab workflows

Samples	Sample preparation	Detection	Insights



Sample technologies #1

PCR

QIAcuity dPCR #2



Genomics / NGS

QIAGEN Digital Insights #1

Diagnostic solutions

QuantiFERON #1

QIAstat-Dx #2

Life Sciences Customers

- Academic labs
- Government research labs
- Pharma / Biotech
- Forensics / Human ID

~$6 bn
total addressable market (2025)

Molecular Diagnostics Customers

- Hospitals / Decentralized healthcare
- Reference labs
- Pharma partnerships
- Public health agencies

~$6 bn
total addressable market (2025)

Current market segment position

Strategy: Committed to solid profitable growth

Our 2028 targets

~7%
Net sales CER CAGR (2024-28)

≥31%
Adj. operating income margin CER (2028)

Ongoing focus on **growth pillars** to **sustain profitable growth**

› **At least $2 bn**
net sales CER from pillars in 2028

Drive **efficiency and digitization** to fuel growth investments and profitability

› **At least 250 bps**
adj. operating income margin expansion 2024-28

Ensure **disciplined capital allocation** for growth and shareholder value

› **At least $1 bn**
of returns to shareholders 2024-28 (absent M&A)

BPS – Basis points I CAGR – Compound annual growth rate I CER – Constant exchange rates

Focusing on attractive opportunities in molecular testing

Product groups	**Sample technologies**	**Diagnostic solutions**	**PCR / Nucleic acid amplification**	**NGS / Genomics**
2025 sales	**$661 mn**	**$803 mn**	**$309 mn**	**$242 mn**

Growth pillars

Accelerate investments for growth

QIAcuity #2

Microplate-based digital PCR



QIAstat-Dx #2

Syndromic PCR testing with unrivaled ease

QIAGEN Digital Insights (QDI) #1

Powerful analytics to understand genomics



Build on proven leadership

Sample technologies #1

Comprehensive portfolio

QuantiFERON #1

Leading immune response monitoring (incl. TB)

Current market segment position

QIAcuity dPCR

dPCR – Capturing share from qPCR and NGS markets

Quantitative PCR (qPCR)	QIAcuity dPCR	Next-generation sequencing (NGS)
e.g., Gene expression	Making high-precision PCR more accessible	e.g., Liquid biopsy
– Lower accuracy and precision	**High sensitivity and precision** More accurate than qPCR	+ In-depth insights and high precision
+ Fast time-to-result at low cost	**Rapid and cost-effective** Faster and lower cost than NGS	– Slow time-to-result at high cost
~$2.7 bn qPCR 2025 total addressable market(1)	**~$0.6 bn** dPCR 2025 total addressable market(1)	**~$1.9 bn** NGS consumables 2025 total addressable market(1)

>15% CAGR (2024-28)

QIAcuity bridges the significant opportunity between qPCR and NGS

(1) Total addressable market incl. research and clinical customer segments (QIAGEN market estimates) I NGS – Next-generation sequencing

Instruments tailored to varying customer segments

Scalable systems
Low- to high-throughput capabilities

Ease of use
Fully integrated automation portfolio

DNA integrity analysis
Built-in software allows quick assessment of DNA or vector quality

Fastest time to result
Over twice as fast vs. droplet digital PCR(1)

QIAcuity One

QIAcuity Four

QIAcuity Eight

QIAcuityDx

Academia
Overcoming entry barrier vs. qPCR

Translational and cancer research
Exploring use of dPCR vs. NGS

Biopharma
Precision / speed benefits vs. qPCR / NGS

Clinical labs / hospitals
Validated for diagnostic applications

>2,700 validated QIAcuity dPCR assays

GeneGlobe custom assay design tool

Key achievements

>3,200
cumulative placements since 2020 launch

>400
customers with multiple instruments (2025)

>1,100
publications referencing QIAcuity dPCR (2025)

(1) Compared to QX200 dPCR

Gene expression: Growing opportunity for QIAcuity

What is gene expression?

Measuring which genes are turned on or off and by how much – Essential to understanding biology

A large and growing market

~$2.7 bn qPCR addressable market in 2025

Gene expression accounts for the majority of qPCR use cases

Overcome qPCR limitations

Improve over qPCR accuracy and precision

QIAcuity dPCR: Expanding beyond qPCR limitations

As easy as qPCR

No standard curves or reference genes

As fast as qPCR

Fits seamlessly into established workflows

Accurate and precise

Detect subtle changes with confidence

More targets at once

Higher multiplexing in a single reaction

Highly reproducible

Consistent across studies and labs

Significant investments into QIAcuity dPCR

≥$250 mn
QIAcuity
net sales CER target (2028)

Accelerate commercialization	Target new applications	Extend into clinical use
>3x increase of sales specialists for market penetration	**Launch new assays** for gene expression and Cell and Gene Therapy applications	**QIAcuityDx** enabling MRD and monitoring applications (e.g., liquid biopsy)
Accelerate market through **customer education** in biopharma and translational	**Maximize value of GeneGlobe** >10 million predesigned assays with unlimited customization	**Menu expansion** Opening platform to diagnostic partners

CER – Constant exchange rates I MRD – Minimal residual disease

QIAstat-Dx

Identifying unknown diseases at speed and ease

~$2.4 bn
syndromic testing 2025 total addressable market

Use case:
3-year-old with severe but unspecific GI symptoms

Traditional testing
Slow diagnosis and treatment decisions can lead to complexities

Day 1

Multiple tests to identify disease

Day X

Late diagnosis and delay in starting the right **treatment**

Syndromic testing
Fast diagnosis enabling better treatment decisions

Day 1

One test within **one hour**

Quick diagnosis for accurate **treatment**

- Better for patients and physicians
- Reduces healthcare costs

GI – Gastrointestinal

QIAstat-Dx offers differentiated features

Strong product capabilities

Specification	QIAstat-Dx	Competition
Hands-on time	~1 min	>5 min
qPCR	✓	✗
Amplification curves / Ct values	✓	✗
Time to result	~1 hour	~1 hour

Key differentiators

Workflow efficiency and safety for **robust results**

Additional pathogens on panels for **broader coverage**

Lab connectivity for **remote results**

Lower noise level for **better lab environment**

Key achievements

>5,200
cumulative placements since launch

>75%
of customers use more than 3 panel types

~100
countries with QIAstat-Dx customers

Expanding global presence and differentiated menu

≥$200 mn
QIAstat-Dx
net sales CER target (2028)

Grow installed customer base

Small hospitals
Public health labs

Medium hospitals
Regional reference labs

Large hospital networks
National reference labs

Low-throughput customers → High-throughput customers

Drive menu expansion

	Complete Panels						Mini Panels	
	Respiratory	GI	Meningitis	Blood culture	cUTIs	Pneumonia	Resp. 5 Mini[1]	2x GI 5 Mini[2]
EU	✓	✓	✓	✓	2026	2028		
US	✓	✓	✓	✓	2026	2028	✓	✓

✓ Already launched 202X: Submission date

CER – Constant exchange rates | cUTI – Complicated Urinary Tract Infection | GI – Gastrointestinal | Resp. – Respiratory
(1) Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), Rhinovirus, SARS-CoV-2 version | (2) *Campylobacter*, *Salmonella*, Shiga-like toxin *E. coli* (STEC), *Shigella*, *Yersinia enterolitica* or Norovirus versions

QIAGEN Digital Insights

Powerful analytics to understand genomics

QIAGEN unlocking the power of genomics

In 2003, the **first** human genome took

13 years

>$1 bn / genome

Today, **any** human genome can be read in

5 hours

$100 / sequencing run

Development



The challenge:

Bottleneck in scaling data interpretation

Up to 324 million possible variants

Research at ~1 hour per variant

QDI: #1 in solving the bioinformatics challenge

Every day

150,000 users

gain valuable disease insights

Every month

80,000 reports

created by our clinical customers

Top bioinformatics for research to clinical customers

Addressing large customer base

Research –
Scientific discovery

- Pharma / Biotech
- Academia
- Government research

Clinical –
Patient outcomes

- Clinical testing labs
- Hospitals
- Government labs

Delivering QDI software solutions for NGS workflow



Sample prep

QIAGEN kits

Library prep

QIAGEN kits



NGS analysis

NGS partners

Bioinformatics

QIAGEN Digital Insights

Software insights drive the next actions

Key achievements

#1
in bioinformatics software for research and clinical

6
market-leading and highly profitable products

>70
countries with QDI customers

NGS – Next-generation sequencing

Case study: Research

Advancing drug development

Pharma challenge

Key to understanding **disease pathways, targets and measure changes**

Significant number of **failures without the ability of foresight**

Drug research market is worth **$60 bn with significant growth expected**

QDI pivotal to drug discovery

- Over **50,000 scientific publications** cite our software
- **25 of the Top 25** Pharma companies use QDI



Within **2 minutes**,
software **indicates specific diseases** that **could be treated**

Case study: Clinical

Enhancing patient outcomes

Patient situation

Profile
Male (early 70s)

Diagnosis
Leukemia linked to rare gene mutation

Therapy outlook
Standard chemotherapy not expected to be effective

QDI-enhanced patient outcome

- Mutation **identification** and **recommendation** by QDI
- Targeted therapy leading to life-saving **disease remission**

QIAGEN Clinical Insights report



Genoox: The AI-powered software platform

Speed	Accuracy	Confidence
Optimized for clinical turnaround	**AI workflows augmented by scientists**	**Proven across >5.5 million reports**
Continuous feedback through users	AI outputs validated by expert review	Gold-standard knowledge databases
How we win	**How we win**	**How we win**
Optimized workflows User-refined oncology and hereditary experiences **Augmented intelligence** AI and scientists working together across analysis and reporting	**Best-informed AI** Powered by the industry's most trusted QDI content **Continuous peer review** More than 30,000 users review and contribute	**Highest-quality content** More than 150 expert curators augmented by AI **Exclusive knowledge access** Reports built on premium genomic databases

Focus on "SaaS" subscription model and AI to expand market leadership

2028 goals

- ☐ Deepen global **commercial reach and SaaS transition** for sustainable growth
  +40% SaaS sales specialists
- ☐ Invest in **new AI** technologies
  >14 AI-enabled applications
- ☐ Extend **curated knowledge** leadership
  >12 mn relevant genomic variants

Coming in 2026

4 new **AI-enhanced commercial offerings**

Agentic AI interface for NGS data analysis software(1)

3 AI-enabled Omics Knowledge Base offerings

(1) Ingenuity Pathway Analysis software (IPA)

Investing to extend market leadership

≥$200 mn
QDI
net sales CER target (2028)

Extend leadership in curated knowledge

Expand QIAGEN knowledge base into spatial, proteomics and microbiome

>12 mn
relevant genomic variants for analytics

Deepen global commercial reach

Adopt SaaS go-to-market approach

>40%
new sales specialists dedicated to SaaS sales

Invest in new AI and other technologies

Continue advancing software portfolio

~20%
of QDI sales to be invested into R&D

SaaS – Software-as-a-Service

Sample technologies: #1 in the first step of every molecular workflow

Laboratory workflow



Customers

Academia / Research | **Pharma** | **Applied testing** | **Clinical**

Selected key applications[1]

Oncology[2]	Microbiome	Infectious diseases	Biopharma	Human ID / Forensics
>$600 mn HSD growth	>$100 mn HSD growth	~$250 mn MSD growth	>$300 mn HSD growth	>$125 mn DD growth

Addressing a growing $2 bn+ market opportunity as high-value applications build momentum

(1) Based on market segment reports; application areas overlapping I (2) Including research and clinical I dPCR – digital PCR I HSD – High single-digit I MSD – Mid single-digit I DD – Double-digit

QIAGEN leading the way in sample preparation

Comprehensive consumables portfolio

ANY
biological sample

e.g., tissue, cells, blood, serum, wastewater

>350
different sample kits

for manual and automated processing

ANY
DNA / RNA
target analytes

including variations

State-of-the-art automation portfolio

Manual kits	QIAcube Connect	EZ2 Connect	QIAcube HT	QIAsymphony
				

Low-throughput → Mid-throughput → High-throughput

~60%
manual kits

~40%
automated solutions

Key achievements

>120 mn
QIAGEN preparations sold per year

>31,400
cumulative instrument placements (>11,000 since 2019)

>50,000
annual mentions in peer reviewed publications

Scaling automation for the future

Key initiatives

Expand state-of-the-art portfolio

Update automation systems with next-gen applications

Enter high-throughput market



QIAmini

Launch 2026

Rapid, entry-level automation helping labs of any size transition to automated sample prep

>100,000 placements(1)

QIAsymphony Connect

Launched in 2025

Advanced automation enabling liquid biopsy workflows with higher throughput and sensitivity

>5,000 placements(1)

QIAsprint Connect

Launched in 2026

Entry into high-throughput automation with fast processing and maximum workflow flexibility

>10,000 placements(1)

(1) Opportunity for instrument placements

On the offense expanding our top automation portfolio

≥$750 mn
Sample technologies net sales CER target (2028)

On track

QIAsprint Connect
Launch February 2026

- High-throughput automation (up to 192 similar samples)
- First orders received in 2025 ahead of 2026 market entry
- Fast purification in only 30-45 min

QIAsymphony Connect
Commercial launch July 2026

- Fully automated digital sample tracking
- Up to 50% higher throughput for some liquid biopsy runs
- Targeting high-value applications across LS and Dx

QIAmini
Launch Fall 2026

- Rapid entry-level automation (designed for smaller labs)
- Robust benchtop system to support manual conversion
- Load-and-go processing with pre-filled cartridges



CER – Constant exchange rates

Extending our Sample tech leadership with single-cell solutions

~$2.1 bn
Expected single-cell market by 2029

~10% CAGR
2024 - 2029

3,000+
Leading labs in 40+ countries using Parse solutions

2.5 bn+
Cells prepared annually through GigaLab

Driving the next wave of growth

Expanding
Key applications in oncology, immunology and neurology

AI-driven
Generates data fueling AI-powered drug discovery

Adopted
By all top 50 research institutions(1) and top 10 pharma companies(2)

Synergistic
Extends Sample technologies leadership and integrates with QDI

Parse Biosciences accelerates QIAGEN's entry into a **high-growth, high-margin** market segment, creating a new engine for **long-term growth**

(1) By 2024 NIH Awards I (2) By 2023 revenues

Parse: Breaking single-cell limits

Scalable

Designed for next-gen biology

>1,000x higher single-cell scale reported over the last 10 years

How we win

Instrument-free

Without hardware scaling limits

Hundred-million-cell scale

With 100 mn and 300 mn cells programs

High quality

Validated for consistent performance

Data quality determines value at scale for customers

How we win

Proven quality

Across large multi-day studies

Standardized

With end-to-end quality control

AI ready

Built for translational reality

AI models need biologically diverse training data

How we win

Multi-cohort datasets

Across diseases and conditions

Sample compatibility

Proven with blood and tissue material

QuantiFERON

Tuberculosis: A highly contagious and lethal bacterial infection

1 in 4
people have a latent TB bacterial infection

1 in 10
of these people will develop an active TB bacterial infection

#1 cause of death
among infectious diseases

~$1.6 bn
annual latent TB market opportunity(1)

Broad health risk



Global relevance



Latent TB testing stops spread of active TB and protects public health

(1) Latent TB testing total addressable market in 2026 I TB - Tuberculosis

Best-positioned test for latent TB detection

Advantages over skin test

Specification	QuantiFERON blood test	Tuberculin skin test
Customizable automated workflow	✓	✗
High accuracy and specificity	✓	✗
Only one patient visit	✓	✗
Electronic results	✓	✗
Quality-assured laboratory test	✓	✗

Advantages over blood-based competitors

>2,700 citations
in publications underscoring clinical value

>130 countries
with QuantiFERON customers across 3,100 labs

>3 endorsements
including WHO, U.S. CDC and IPPA

>120 patents
in 34 countries beyond 2030

CDC – U.S. Centers for Disease Control and Prevention I IPPA – International Panel Physicians Association I WHO – World Health Organization

Key achievements

$503 mn
2025 net sales (+110% vs. 2019)



>160 mn
QuantiFERON-TB tests since launch

WHO
endorsement for QuantiFERON-TB

Driving skin test conversion with unrivaled automation

≥$600 mn
QuantiFERON net sales CER target (2028)

Increase customer base

Leading automation advantage

Partnership with **Diasorin** to **expand into Lyme disease (EU and U.S.)**

Drive TB market conversion

Large potential in skin test conversion



~$1.6 bn market size(1) | **QuantiFERON**

New in 2027

- **Decentralized TB test** for **emerging markets**
- **Fully automated test** with Inpeco and Diasorin
- **QuantiFERON AI tool for risk stratification**

(1) Latent tuberculosis testing market estimate (2026) I CER – Constant exchange rates

Creating a complete QuantiFERON ecosystem



Blood collection | Aliquotation | Incubation | Centrifugation | Detection | Data analysis

Current QuantiFERON workflow

QIAGEN | TECAN. HAMILTON | Manual intervention steps | QIAGEN Diasorin

Announcing a new QuantiFERON ecosystem

NEW

QIAGEN inpeco
Fully automated Sample to Insight workflow

QIAGEN Diasorin
New chemistry

QIAGEN
AI-enabled risk stratification

Expanded ecosystem enables full automation and improves efficiency

Addressing the need to **improve pre-analytical steps** in labs

QIAGEN **fully automates** the process with Inpeco and Diasorin partnerships

Process automation can be adapted to **specific customer needs**

Ambition to be the first FDA-approved, CE-marked **fully automated TB test**

Launch 2027

Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028

Operational excellence
Positioning QIAGEN for stronger profitable growth

Organizational design
Foster agility and ownership in decision-making

Portfolio streamlining
Continued disciplined portfolio management

Process optimization
Drive key process scalability with S/4HANA upgrade

Site network strategy
Improve capacity utilization through network optimization

Digitization
Accelerating growth and efficiency across QIAGEN

>3.5 million
commercial website visits / year with ~22% increase (2019-25)

~67%
digital transaction share enabling **touchless orders**



~30
dedicated cross-functional AI initiatives, including:

- Manufacturing
- Regulatory
- Customer service

Executing our strategy with empowered QIAGENers

~5,700
QIAGENers

~50%
new top leaders since 2020

~15%
with QIAGEN for >15 years

Expand our **culture of empowerment**

Foster **accountability** and **decentralized decision-making**

Embracing ESG for all stakeholders

Environmental responsibility

Net zero
carbon emission target (2050)

Investing in people

37%
female leadership (2025)

Serving society

75.7
Service NPS-T score exceeding goal of 64.5 (2025)

Business with integrity

94%
completion rate for Code of Conduct training (2025)

Top ESG ratings

Corporate ESG Performance Prime
RATED BY ISS ESG

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

MSCI ESG RATINGS AAA
CCC | B | BB | BBB | A | AA | AAA

COMMITTED ecovadis Sustainability Rating

SUSTAINALYTICS
ESG Risk Rating
13.0 Low Risk
Negligible | Low | Medium | High | Severe
0-10 | 10-20 | 20-30 | 30-40 | 40+

Climate CDP 2025 A-
Water CDP 2025 B-

Q2 2026 results

Committed to solid profitable growth

August 5, 2026

Forward looking and intended use statements

Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Regulation G: In this presentation, QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. Adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

Q2 2026: Solid performance exceeding outlook

Growth

Q2 2026 net sales ahead of outlook with growth pillars driving performance

- 0% CER, ahead of the outlook for ~-2% CER decline
- Sales from growth pillars increased 5% CER, led by Sample tech, QIAcuity and QDI
- QuantiFERON grew 1% CER, with solid trends outside immigration testing

Net sales

$535 mn
($531 mn CER)
0% CER
vs. Q2 2025

Profitability

Improvements in adj. diluted EPS and sequential margin expansion

- **Margin:** 29.4% adj. operating income margin vs. 29.9% in Q2 2025, while investing in future growth
- **Adj. diluted EPS:** $0.62 CER ahead of outlook for ≥$0.60 CER
- **Very strong operating cash flow**[(1)]: $301 mn in H1 2026 while investing in efficiency programs and higher inventory levels

Adj. diluted EPS

$0.62
($0.62 CER)
+3%
vs. Q2 2025

Adj. operating margin

29.4%
Q1 2026: 27.4%

Outlook

2026: Reaffirming net sales and adjusted diluted EPS outlook

- Net sales: ~+1-2% CER driven by expansion from pillars
- Adjusted diluted EPS: ≥$2.43 CER

Operating cash flow

H1: $301 mn
Strong cash generation

CER – Constant exchange rates | (1) Including about $20 million of cash out from efficiency programs.

Q2 2026: Sales performance and key developments

Sales by product group

(In $ millions at actual rates)



Key developments

Sample technologies	• +9% CER growth, +3% CER growth excl. Parse • Automated consumables delivered high teens CER growth
QuantiFERON	• +1% CER growth with solid trends outside immigration testing • Growth across core testing groups offset immigration weakness
QIAstat-Dx	• -7% CER decline against a strong respiratory comparison • Growing demand for the GI and Meningitis panels
QIAcuity	• Double-digit CER growth on continued consumables demand • Continued adoption across research and clinical applications
QDI	• Solid single-digit CER growth led by clinical applications • Advancing AI capabilities through strategic partnerships

(1) Q2: Net sales $531 million CER (0% at constant exchange rates, 0% at actual rates)
CER – Constant exchange rates

Q2 2026: Portfolio developments

Sample technologies:
Expanding automated sample preparation

Progressing rollout of new automation systems

- **QIAsymphony Connect:** Commercial launch of new IVD-compliant system
- **QIAsprint Connect:** First instrument placements with very positive feedback
- **QIAmini**: On track for launch in Fall 2026

QIAGEN Digital Insights:
Accelerating biomedical research

NVIDIA collaboration to advance AI capabilities

- **Knowledge bases:** Combining QDI content with NVIDIA BioNeMo
- **Research:** Supporting target identification and biomarker discovery

QIAstat-Dx:
Advancing syndromic testing solutions

Launch of QIAstat-Dx panels and expansion into new testing areas

- **Bloodstream infections:** Portfolio expansion with BCID GPF Plus AMR panel (Europe)
- **Cyclospora outbreak:** Supporting U.S. response with the GI panel

Q3 and FY 2026: Outlook and assumptions

(As of August 5, 2026)	Q3 2026 outlook	FY 2026 outlook
Net sales	**~+1-2% CER**	**~+1-2% CER**
Anticipated currency impact[1]	Negative impact of ~-1 ppt	Positive impact of ~+1 ppt
Adjusted diluted EPS[2]	**≥$0.62 CER**	**≥$2.43 CER**
Anticipated currency impact[1]	Neutral	Neutral
Adjustments to operating income (In $ millions):		
Business integration and acquisition-related items	~$5 mn	~$15 mn
Restructuring-related items	~$10 mn	~$55 mn
Amortization of acquired intellectual property	~$15 mn	~$62 mn
Adjusted tax rate (%)	**~17-18%**	**~17-18%**
Weighted average number of diluted shares outstanding (Based on $43.00 share price)	**~208 million**	**~209 million**

(1) Based on exchange rates as of August 3, 2026.

(2) QIAGEN reports adjusted results to provide additional insight into its performance. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.

Appendix

2026 sales outlook: H1 vs. H2 updated perspectives



Multiple levers to improve sales trends in H2 2026

CER – Constant exchange rates I ppts – Percentage points I (1) QIAstat-Dx and QIAcuity launches

Disciplined capital allocation to drive long-term value

Organic investments	**Profitable targeted investments** into growth pillars and digitization to fuel profitable business expansion
Focused M&A	**Value-creating transactions** to enhance portfolio and maintain leadership
Shareholder returns	**>$1.1 bn returned to shareholders** through synthetic share buybacks and dividends since 2024

Annual dividend

- Dividend approval at the AGM in June 2026
- $0.35 dividend per share (~$72 mn payment in July 2026)

Share repurchase

- Additional shareholder authorization secured for share repurchases over the next 18 months

Q2 2026: Consolidated Statements of Income (unaudited)

(In $ thousands, except share data)	Three months ended June 30, 2026	Three months ended June 30, 2025
Net sales	**535,040**	**533,540**
Cost of sales:		
Cost of sales	181,973	185,951
Acquisition-related intangible amortization	12,681	13,303
Total cost of sales	**194,654**	**199,254**
Gross profit	**340,386**	**334,286**
Operating expenses:		
Sales and marketing	116,675	118,097
Research and development	50,429	47,750
General and administrative	30,093	30,648
Acquisition-related intangible amortization	2,339	1,817
Restructuring, acquisition, integration and other, net	8,449	14,072
Total operating expenses	**207,985**	**212,384**
Income from operations	**132,401**	**121,902**
Adjusted income from operations	*157,059*	*159,503*
Other income (expense):		
Interest income	9,361	13,859
Interest expense	(10,022)	(7,605)
Other income (expense), net	365	(1,335)
Total other (expense) income, net	**(296)**	**4,919**
Income before income tax expense	**132,105**	**126,821**
Adjusted income before income tax expense	*157,082*	*164,506*
Income tax expense	**28,704**	**30,571**
Adjusted income tax expense	*27,877*	*32,587*
Net income	**103,401**	**96,250**
Adjusted net income	*129,205*	*131,919*
Diluted earnings per share	**$0.50**	**$0.44**
Adjusted diluted earnings per share	*$0.62*	*$0.60*
Shares used in computing diluted earnings per share (in thousands)	**207,828**	**218,183**

H1 2026: Consolidated Statements of Income (unaudited)

(In $ thousands, except share data)	Six months ended June 30, 2026	Six months ended June 30, 2025
Net sales	**1,027,360**	**1,016,996**
Cost of sales:		
Cost of sales	351,432	347,245
Acquisition-related intangible amortization	25,939	26,784
Total cost of sales	**377,371**	**374,029**
Gross profit	**649,989**	**642,967**
Operating expenses:		
Sales and marketing	231,281	224,431
Research and development	98,690	91,533
General and administrative	57,875	62,256
Acquisition-related intangible amortization	4,667	3,610
Restructuring, acquisition, integration and other, net	40,650	23,888
Total operating expenses	**433,163**	**405,718**
Income from operations	**216,826**	**237,249**
Adjusted income from operations	*291,793*	*303,700*
Other income (expense):		
Interest income	19,923	29,249
Interest expense	(21,073)	(14,899)
Other income (expense), net	2,258	(5,229)
Total other income, net	**1,108**	**9,121**
Income before income tax expense	**217,934**	**246,370**
Adjusted income before income tax expense	*293,583*	*315,390*
Income tax expense	**46,490**	**59,362**
Adjusted income tax expense	*51,788*	*62,447*
Net income	**171,444**	**187,008**
Adjusted net income	*241,795*	*252,943*
Diluted earnings per share	**$0.82**	**$0.85**
Adjusted diluted earnings per share	*$1.16*	*$1.15*
Shares used in computing diluted earnings per share (in thousands)	**208,953**	**219,186**

2026: Quarterly sales by product group

(In $ millions at actual rates / change in actual, CER rates)	Q1 2026			Q2 2026			Q3 2026			Q4 2026			FY 2026		
	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER
Sample technologies	170	13%	9%	182	9%	9%							352	11%	9%
Diagnostic solutions[1]	185	-1%	-4%	204	-1%	-2%							389	-1%	-3%
Of which QuantiFERON	*113*	*-3%*	*-5%*	*131*	*2%*	*1%*							*244*	*0%*	*-2%*
Of which QIAstat-Dx	*36*	*4%*	*-1%*	*32*	*-6%*	*-7%*							*68*	*-1%*	*-4%*
Of which NeuMoDx	*—*	*-100%*	*-100%*	*—*	*-100%*	*-100%*							*—*	*-100%*	*-100%*
Of which Other	*36*	*19%*	*15%*	*40*	*1%*	*0%*							*77*	*8%*	*7%*
PCR/Nucleic acid amplification	69	-9%	-13%	74	-7%	-8%							143	-8%	-11%
Genomics/NGS	57	6%	4%	61	3%	2%							117	5%	3%
Other	12	-31%	-31%	15	-34%	-34%							27	-32%	-33%
Total	**492**	**2%**	**-1%**	**535**	**0%**	**0%**							**1,027**	**1%**	**-1%**

(1) Includes QIAcuity digital PCR Dx revenues in 2026 (Q2: $5 million; H1: $8 million). QIAcuity is split between Diagnostic solutions and PCR / Nucleic acid amplification.
Tables may contain rounding differences. | Percentage changes are to prior-year periods.

2026: Quarterly sales by product type and region

(In $ millions at actual rates / change in actual, CER rates)	Q1 2026			Q2 2026			Q3 2026			Q4 2026			FY 2026		
	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER	Sales	Act.	CER
Product type															
Consumables and related revenues	445	2%	-1%	484	2%	1%							928	2%	0%
Instruments	48	-2%	-6%	52	-10%	-11%							99	-6%	-8%
Geographic region[1]															
Americas	249	-2%	-2%	285	2%	1%							535	0%	0%
Europe / Middle East / Africa	173	8%	0%	178	-1%	-2%							351	3%	-1%
Asia-Pacific / Japan	70	2%	0%	72	-2%	-2%							142	0%	-1%
Total	**492**	**2%**	**-1%**	**535**	**0%**	**0%**							**1,027**	**1%**	**-1%**

(1) Rest of World contributed less than 1% of net sales in Q1, Q2 and H1 2026. | Tables may contain rounding differences.

Q2 and H1 2026: Reconciliation to adjusted results (unaudited)

(In $ millions, except EPS)	Net sales	Gross profit	Operating income	Pre-tax income	Income tax	Tax rate	Net income	Diluted EPS*
Second quarter 2026								
Reported results	535.0	340.4	132.4	132.1	(28.7)	22 %	103.4	0.50
Adjustments								
Business integration, acquisition and restructuring related items (a)		1.2	9.6	9.6	(2.7)		6.9	0.03
Purchased intangibles amortization (b)		12.6	15.0	15.0	(3.7)		11.3	0.05
Non-cash other income, net				0.3	(0.1)		0.2	0.00
Certain income tax items (c)					7.4		7.4	0.04
Total adjustments		13.9	24.7	25.0	0.8		25.8	0.12
Adjusted results	**535.0**	**354.3**	**157.1**	**157.1**	**(27.9)**	**18 %**	**129.2**	**0.62**
First half 2026								
Reported results	1,027.4	650.0	216.8	217.9	(46.5)	21 %	171.4	0.82
Adjustments								
Business integration, acquisition and restructuring related items (a)		3.7	44.3	44.3	(12.6)		31.7	0.15
Purchased intangibles amortization (b)		25.9	30.6	30.6	(7.6)		23.0	0.11
Non-cash other income, net				0.7	(0.2)		0.5	0.00
Certain income tax items (c)					15.1		15.1	0.07
Total adjustments		29.6	75.0	75.7	(5.3)		70.4	0.34
Adjusted results	**1,027.4**	**679.6**	**291.8**	**293.6**	**(51.8)**	**18 %**	**241.8**	**1.16**

Please see footnotes for these tables on the following page.

* Weighted number of diluted shares (Q2 2026: 207.8 million; H1 2026: 209.0 million)

Q2 and H1 2026: Footnotes for reconciliation to adjusted results (unaudited)

(a) Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects including subsequent integration activities at GNX Data Systems, Ltd. (Genoox) and Parse Biosciences (Parse).

(b) Adjustment includes the amortization of Genoox and Parse intangible assets acquired in Q2 2025 and Q4 2025, respectively.

(c) These items represent updates in QIAGEN's assessment of ongoing examinations or other tax items that are not indicative of the Company's normal future income tax expense.

Tables may contain rounding differences.

2026: Quarterly income statement summary

(In $ millions, unless indicated) (Diluted EPS in $ per share)	Q1 2026	Q2 2026	Q3 2026	Q4 2026	FY 2026
Net sales	492.3	535.0			1,027.4
Net sales (CER)	476.7	531.1			1,007.9
Gross profit	309.6	340.4			650.0
Gross profit margin	*62.9%*	*63.6%*			*63.3%*
Adjusted gross profit	325.4	354.3			679.6
Adjusted gross profit margin	*66.1%*	*66.2%*			*66.2%*
Operating income	84.4	132.4			216.8
Operating margin	*17.1%*	*24.7%*			*21.1%*
Adjusted operating income	134.7	157.1			291.8
Adjusted operating margin	*27.4%*	*29.4%*			*28.4%*
Tax rate	21%	22%			21%
Adjusted tax rate	18%	18%			18%
Net income	68.0	103.4			171.4
Adjusted net income	112.6	129.2			241.8
Diluted EPS	0.33	0.50			0.82
Adjusted diluted EPS (CER) ($ per share)	0.54 (0.54)	0.62 (0.62)			1.16 (1.15)
Diluted shares outstanding for EPS calculation	208.9	207.8			209.0

CER - Constant exchange rates | Table may have rounding differences. | Refer to accompanying tables for reconciliation of reported to adjusted figures.

Consolidated Balance Sheets

(In $ thousands, except par value)	June 30, 2026	December 31, 2025
Assets	(unaudited)	
Cash and cash equivalents	768,500	839,005
Short-term investments	25,000	259,913
Accounts receivable, net	389,850	402,608
Inventories, net	311,355	301,888
Prepaid expenses and other current assets	161,922	191,659
Total current assets	**1,656,627**	**1,995,073**
Property, plant and equipment, net	923,043	923,948
Goodwill	2,693,398	2,700,658
Intangible assets, net	352,347	386,431
Other long-term assets	263,787	275,122
Total long-term assets	**4,232,575**	**4,286,159**
Total assets	**5,889,202**	**6,281,232**

(In $ thousands, except par value)	June 30, 2026	December 31, 2025
Liabilities and equity	(unaudited)	
Current portion of long-term debt	16,517	—
Accrued and other current liabilities	485,846	439,481
Accounts payable	79,083	72,656
Total current liabilities	**581,446**	**512,137**
Long-term debt	1,627,105	1,654,428
Other long-term liabilities	322,911	336,513
Total long-term liabilities	**1,950,016**	**1,990,941**
Common shares, EUR 0.01 par value: Authorized – 410,000 shares Issued – 206,801 shares (2026) and 217,685 shares (2025)	2,404	2,529
Additional paid-in capital	956,239	1,436,360
Retained earnings	2,814,982	2,748,390
Accumulated other comprehensive loss	(402,667)	(377,309)
Less treasury shares at cost – 306 shares (2026) and 764 shares (2025)	(13,218)	(31,816)
Total equity	**3,357,740**	**3,778,154**
Total liabilities and equity	**5,889,202**	**6,281,232**

Balance sheet data and metrics		
Group liquidity[1]	793,500	1,098,918
Net debt[2]	850,122	555,510
Leverage ratio[3]	1.1x	0.7x

(1) Group liquidity includes cash, cash equivalents and short-term investments.
(2) Net debt is equal to total outstanding long-term debt minus group liquidity.
(3) Leverage ratio is calculated on trailing four quarters as net debt / adjusted EBITDA.

Consolidated Statements of Cash Flows (unaudited)

Six months ended (In $ thousands)	June 30, 2026	June 30, 2025
Cash flows from operating activities:		
Net income	171,444	187,008
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses acquired:		
Depreciation and amortization	101,766	93,386
Non-cash impairments	15,218	2,537
Amortization of debt discount and issuance costs	1,180	1,124
Share-based compensation	16,618	23,096
Deferred tax (benefit) expense	(3,317)	3,175
Loss on marketable securities	—	968
Other items, net including fair value changes in derivatives	1,615	8,615
Change in operating assets, net	(17,550)	(19,934)
Change in operating liabilities, net	14,345	1,200
Net cash provided by operating activities	**301,319**	**301,175**
Cash flows from investing activities:		
Purchases of property, plant and equipment	(89,813)	(84,092)
Purchases of intangible assets	(2,034)	(1,008)
Purchases of short-term investments	(25,000)	(134,720)
Proceeds from redemptions of short-term investments	259,294	402,057
Cash paid for acquisitions, net of cash acquired	(1,864)	(66,595)
Cash received (paid) for collateral asset	1,257	(36,046)
Purchases of investments, net	(626)	(1,512)
Net cash provided by investing activities	**141,214**	**78,084**

Six months ended (In $ thousands)	June 30, 2026	June 30, 2025
Cash flows from financing activities:		
Capital repayment	(496,749)	(280,086)
Tax withholdings related to vesting of stock awards	(13,945)	(15,227)
Cash received (paid) for collateral liability	1,117	(9,940)
Cash paid for contingent consideration	(2,000)	(9,219)
Other financing activities	(552)	(226)
Net cash used in financing activities	**(512,129)**	**(314,698)**
Effect of exchange rate changes on cash and cash equivalents	(909)	5,699
Net (decrease) increase in cash and cash equivalents	**(70,505)**	**70,260**
Cash and cash equivalents, beginning of period	839,005	663,555
Cash and cash equivalents, end of period	**768,500**	**733,815**
Reconciliation of Free Cash Flow[1]		
Net cash provided by operating activities	301,319	301,175
Purchases of property, plant and equipment	(89,813)	(84,092)
Free Cash Flow	**211,506**	**217,083**

(1) Free cash flow is a non-GAAP financial measure and is calculated from net cash provided by operating activities reduced by purchases of property, plant and equipment.

Q2 and H1 2026: Currency impact

	Net sales (In $ millions / Actual)	Net sales (CER)	Currency exposure (As % of CER sales)	Change (In $ millions)
Q2 2026				
U.S. dollar	309.4	309.4	58%	0.0
Euro	99.0	96.9	18%	-2.1
British pound	17.8	17.7	3%	-0.1
Japanese yen	9.2	10.2	2%	1.0
Other currencies	99.6	96.9	18%	-2.7
Total net sales	**535.0**	**531.1**	100%	**-3.9**
H1 2026				
U.S. dollar	582.4	582.4	58%	0.0
Euro	196.1	184.6	18%	-11.5
British pound	36.5	35.0	3%	-1.5
Japanese yen	21.0	22.3	2%	1.3
Other currencies	191.4	183.6	18%	-7.8
Total net sales	**1,027.4**	**1,007.9**	100%	**-19.5**

CER - Constant exchange rates | Table may have rounding differences.
Other currencies include CAD, DKK, TRY, SEK, CHF, AUD, BRL, CNY, MYR, SGD, KRW, HKD, MXN, ILS, INR, TWD, SAR, THB and ZAR.

Employees as of June 30, 2026

	Americas	Europe / Middle East / Africa	Asia Pacific / Japan / ROW	Total Q2 2026	Total Q1 2026	Change
Production	287	1,070	140	1,497	1,513	-1%
R&D	158	730	51	939	956	-2%
Sales	549	811	694	2,054	2,060	0%
Marketing	77	167	65	309	320	-3%
Administration	72	437	156	665	677	-2%
Total	**1,143**	**3,215**	**1,106**	**5,464**	**5,526**	-1%

Your contacts

Daniel Wendorff
Vice President
Head of Investor Relations

Phone: +49 2103 29 11322
E-mail: daniel.wendorff@qiagen.com

Dr. Domenica Martorana
Associate Director
Investor Relations

Phone: +49 2103 29 11244
E-mail: domenica.martorana@qiagen.com

Alexandra Koenig
Coordinator
Investor Relations

Phone: +49 2103 29 11709
E-mail: alexandra.koenig@qiagen.com

Calendar

Q3 2026 results	November 2026
Q4 2026 results	February 2027

Share information

NYSE:	QGEN
Frankfurt:	QIA
ISIN / CUSIP:	NL0015002SN0 / N72482 156
WKN:	A41HBE

E-mail:
ir@qiagen.com

Internet:
corporate.QIAGEN.com

QGEN
LISTED
NYSE
DAX
TecDAX

www.linkedin.com/company/qiagen

www.x.com/QIAGEN

www.facebook.com/QIAGEN

www.youtube.com/user/QIAGENvideos